NasdaqCM - Delayed Quote USD

Context Therapeutics Inc. (CNTX)

0.1891 -0.0126 (-6.25%)

At close: October 30 at 4:00:01 PM EDT

Trade CNTX on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for CNTX

Previous Close 0.2017
Open 0.2030
Bid 0.1976 x 300
Ask 0.2134 x 300
Day's Range 0.1888 - 0.2030
52 Week Range 0.1888 - 3.6200
Volume 1,012,585
Avg. Volume 1,529,859
Market Cap (intraday) 17.374M
Beta (5Y Monthly) 1.72
PE Ratio (TTM) --
EPS (TTM) -0.4800
Earnings Date --
Forward Dividend & Yield -- (0.00%)
1y Target Est 4.14
Zacks Rating Neutral

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

www.contexttherapeutics.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CNTX

87.14%

S&P 500 (^GSPC)

10.73%

1-Year Return

CNTX

83.27%

S&P 500 (^GSPC)

11.11%

3-Year Return

CNTX

81.64%

S&P 500 (^GSPC)

81.91%

5-Year Return

CNTX

96.72%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue --

Earnings -14.56M

Profit Margin 0.00%

FY25

FY26

-10M

-5M

0.0%

Analyst Price Targets

2.00

4.14 Average

0.1891 Current

5.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 6/16/2026

Analyst Maxim Group

Rating Action Maintains

Rating Buy

Price Action Lowers

Price Target 8 -> 4

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-45.70%
Return on Equity (ttm)

-76.14%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-45.96M
Diluted EPS (ttm)

-0.4800

Balance Sheet and Cash Flow

Total Cash (mrq)

42.99M
Total Debt/Equity (mrq)

0.64%
Levered Free Cash Flow (ttm)

-31.53M

MRAI Marpai, Inc.

2.9590 -3.30%

KTTA Pasithea Therapeutics Corp.

0.3702 +0.16%

BFRI Biofrontera Inc.

0.8729 -6.29%

ENSC Ensysce Biosciences, Inc.

0.4210 -3.88%

PTPI Petros Pharmaceuticals, Inc.

0.0020 0.00%

U.S. markets closed

Context Therapeutics Inc. (CNTX)

Trading disclosure

-20.88%

-36.97%

-91.99%

-87.14%

-83.27%

-96.72%

-95.74%

Context Therapeutics Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch